TRexBio is a discovery stage biotechnology company leveraging cutting edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us to identify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis. TRexBio is headquartered in South San Francisco, California.
Location: United States, California, South San Francisco
Employees: 11-50
Total raised: $219M
Founded date: 2018
Investors 2
| Date | Name | Website |
| 04.07.2025 | Avego | avego.com |
| - | SV Health ... | svhealthin... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 27.01.2026 | - | $50M | - |
| 23.11.2024 | Series B | $84M | - |
| 08.03.2022 | Series A | $26M | - |
| 22.06.2021 | Series A | $59M | - |
Mentions in press and media 15
| Date | Title | Description |
| 28.08.2026 | TRexBio Announces Positive Topline Results from First-in-Human Phase 1a Study of TRB-061, a TNFR2 Agonist in Clinical Development for Atopic Dermatitis | SOUTH SAN FRANCISCO, Calif., August 26, 2026 – TRex Bio, Inc. (“TRexBio”), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines, today announced unblinded topl... |
| 31.01.2026 | TRexBio Secures $50M to Accelerate Treg-Targeted Immunotherapy Pipeline | TRexBio secured $50 million. This clinical-stage biotech develops precision immunoregulatory medicines. Its focus: tissue regulatory T cell (Treg) biology. Funding fuels clinical and preclinical pipeline advancement. Lead program TRB 061, a... |
| 27.01.2026 | TRexBio Closes $50 Million Financing to Support a Growing Clinical-Stage Immunology Pipeline of Tissue-Targeted Treg Therapeutics | SOUTH SAN FRANCISCO, January 27, 2026 – TRex Bio, Inc. (“TRexBio”), a clinical-stage biotechnology company discovering and developing precision immunoregulatory medicines based on tissue Treg biology, today announced the close of an oversub... |
| 27.01.2026 | TRexBio Raises $50M in Funding | TRexBio, a San Francisco, CA-based clinical-stage biotechnology company, raised $50M in funding. Backers included new investors Janus Henderson Investors, Balyasny Asset Management L.P. and Affinity Asset Advisors, as well as existing inves... |
| 23.11.2024 | TRexBio: $84 Million (Series B) Closed To Decode Human Tissue Immune Biology | TRex Bio – a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics – announced the closing of an oversubscribed $84 million Series B funding round. This funding was led by Delos Capital, with additi... |
| 14.11.2024 | Navigating the Future of Biopharma: Sobi's Meeting and TRexBio's Funding Surge | In the ever-evolving landscape of biopharmaceuticals, two significant events recently captured the industry's attention. Swedish Orphan Biovitrum AB (Sobi) announced an Extraordinary General Meeting, while TRexBio secured a hefty $84 millio... |
| 14.11.2024 | TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development | SOUTH SAN FRANCISCO, November 13, 2024 – TRex Bio, Inc. (“TRexBio”), a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, today announced the close of an oversubscribed $84 million Series B fina... |
| 14.11.2024 | TRexBio Raises $84M in Series B Financing | TRexBio, a San Francisco, CA-based biotechnology company decoding human tissue immune biology to create new therapeutics, raised $84M in Series B funding. The round was led by Delos Capital with participation from Avego BioScience Capital, ... |
| 13.11.2024 | TRexBio Announces $84 Million Series B | SOUTH SAN FRANCISCO, CA, TRex Bio, a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, announced the close of an oversubscribed $84 million Series B financing round. The financing was led by D... |
| 26.06.2024 | TRexBio Announces Collaboration Partner Lilly Has Initiated a Phase 1 Study of TRB-051 for Autoimmune and Inflammatory Diseases | SOUTH SAN FRANCISCO, June 26, 2024 – TRex Bio, Inc. (“TRexBio”), a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, today announced that collaboration partner Eli Lilly and Company (“Lilly”) h... |
Show more